FDA ushers in new lymph-node mapper for cancer patients

The FDA granted its blessing to Lymphoseek, the first new lymph-node mapping drug in more than 30 years. The Navidea Biopharmaceuticals ($NAVB) product uses a receptor-targeted radioactive tracer to identify nodes that contain cancer cells, in patients who are undergoing surgery. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.